JP2018525367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525367A5 JP2018525367A5 JP2018504105A JP2018504105A JP2018525367A5 JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5 JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018504105 A JP2018504105 A JP 2018504105A JP 2018525367 A5 JP2018525367 A5 JP 2018525367A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 72
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 22
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 22
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 17
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 9
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- 201000002528 pancreatic cancer Diseases 0.000 claims description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 4
- 102000048362 human PDCD1 Human genes 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198384P | 2015-07-29 | 2015-07-29 | |
| US62/198,384 | 2015-07-29 | ||
| US201662352637P | 2016-06-21 | 2016-06-21 | |
| US62/352,637 | 2016-06-21 | ||
| PCT/IB2016/054487 WO2017017623A1 (en) | 2015-07-29 | 2016-07-27 | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525367A JP2018525367A (ja) | 2018-09-06 |
| JP2018525367A5 true JP2018525367A5 (enExample) | 2019-09-05 |
| JP6840127B2 JP6840127B2 (ja) | 2021-03-10 |
Family
ID=56682136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504105A Expired - Fee Related JP6840127B2 (ja) | 2015-07-29 | 2016-07-27 | がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11001628B2 (enExample) |
| EP (1) | EP3328425B1 (enExample) |
| JP (1) | JP6840127B2 (enExample) |
| KR (1) | KR20180034426A (enExample) |
| CN (1) | CN108136003A (enExample) |
| AU (1) | AU2016300208B2 (enExample) |
| BR (1) | BR112018000212A2 (enExample) |
| CA (1) | CA2991857A1 (enExample) |
| CL (1) | CL2018000222A1 (enExample) |
| IL (1) | IL256691A (enExample) |
| JO (1) | JO3784B1 (enExample) |
| MX (1) | MX2018001263A (enExample) |
| PH (1) | PH12018500174A1 (enExample) |
| RU (1) | RU2742494C2 (enExample) |
| SA (1) | SA518390834B1 (enExample) |
| TN (1) | TN2017000554A1 (enExample) |
| TW (1) | TWI735456B (enExample) |
| WO (1) | WO2017017623A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| HK1250033A1 (zh) | 2015-07-13 | 2018-11-23 | Cytomx Therapeutics Inc. | 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法 |
| KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| AR112603A1 (es) | 2017-07-10 | 2019-11-20 | Lilly Co Eli | Anticuerpos biespecíficos inhibidores de punto de control |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR102767594B1 (ko) | 2018-07-12 | 2025-02-12 | 코버스 파마슈티칼스, 인크. | 아데노신 경로 활성화를 갖는 암의 검출 및 치료 방법 |
| CN112654365A (zh) | 2018-07-12 | 2021-04-13 | 科尔沃斯制药股份有限公司 | 用于检测和治疗具有腺苷途径激活的癌症的方法 |
| WO2020044252A1 (en) * | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| JP2022519385A (ja) * | 2019-02-12 | 2022-03-23 | ノバルティス アーゲー | Ｔｎｏ１５５及びｐｄ－１阻害剤を含む医薬組合せ |
| JP2022534889A (ja) | 2019-05-24 | 2022-08-04 | ファイザー・インコーポレイテッド | Ｃｄｋ阻害剤を使用した組合せ療法 |
| WO2020252349A1 (en) * | 2019-06-13 | 2020-12-17 | Cytomx Therapeutics, Inc. | Use of an activatable anti-pdl1 antibody and an anti-ctla-4 antibody in a combination therapy for the treatment of cancer |
| JP2022537151A (ja) * | 2019-06-13 | 2022-08-24 | シートムエックス セラピューティクス，インコーポレイテッド | 癌の処置のためのネオアジュバント併用療法での活性化可能抗ｐｄｌ１抗体および抗ｃｔｌａ－４抗体の使用 |
| WO2021226984A1 (zh) | 2020-05-15 | 2021-11-18 | 三生国健药业（上海）股份有限公司 | 一种抗pd-1和pd-l1的四价双特异性抗体 |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| RU2401277C2 (ru) * | 2004-01-07 | 2010-10-10 | Чирон Корпорейшн | Не мышиное анти-m-csf-антитело (варианты), его получение и использование |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP2061512B1 (en) * | 2006-08-23 | 2019-10-02 | Yeda Research And Development Co. Ltd. | Conjugates of rgd peptides and (bacterio)chlorophyll photosensitizers and their uses |
| AU2007296259A1 (en) * | 2006-09-15 | 2008-03-20 | Janssen Pharmaceutica Nv | Combinations of class-I specific histone deacetylase inhibitors with proteasome inhibitors |
| CA2715166C (en) | 2008-02-11 | 2017-05-16 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| KR102232153B1 (ko) * | 2013-08-20 | 2021-03-24 | 머크 샤프 앤드 돔 코포레이션 | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
-
2016
- 2016-07-27 KR KR1020187002247A patent/KR20180034426A/ko not_active Ceased
- 2016-07-27 CA CA2991857A patent/CA2991857A1/en not_active Abandoned
- 2016-07-27 BR BR112018000212A patent/BR112018000212A2/pt not_active IP Right Cessation
- 2016-07-27 JP JP2018504105A patent/JP6840127B2/ja not_active Expired - Fee Related
- 2016-07-27 RU RU2018106876A patent/RU2742494C2/ru active
- 2016-07-27 WO PCT/IB2016/054487 patent/WO2017017623A1/en not_active Ceased
- 2016-07-27 AU AU2016300208A patent/AU2016300208B2/en not_active Ceased
- 2016-07-27 EP EP16750495.0A patent/EP3328425B1/en active Active
- 2016-07-27 TN TNP/2017/000554A patent/TN2017000554A1/en unknown
- 2016-07-27 MX MX2018001263A patent/MX2018001263A/es unknown
- 2016-07-27 CN CN201680044470.5A patent/CN108136003A/zh active Pending
- 2016-07-27 US US15/879,064 patent/US11001628B2/en not_active Expired - Fee Related
- 2016-07-28 JO JOP/2016/0162A patent/JO3784B1/ar active
- 2016-07-29 TW TW105124178A patent/TWI735456B/zh not_active IP Right Cessation
-
2018
- 2018-01-01 IL IL256691A patent/IL256691A/en unknown
- 2018-01-23 PH PH12018500174A patent/PH12018500174A1/en unknown
- 2018-01-26 CL CL2018000222A patent/CL2018000222A1/es unknown
- 2018-01-29 SA SA518390834A patent/SA518390834B1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525367A5 (enExample) | ||
| RU2018106876A (ru) | Новая комбинация для применения при лечении злокачественного новообразования | |
| JP2018127467A5 (enExample) | ||
| JP2019508013A5 (enExample) | ||
| JP2018507220A5 (enExample) | ||
| JP2016531150A5 (enExample) | ||
| JP2018501197A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| JP2017529838A5 (enExample) | ||
| RU2018105846A (ru) | Комбинация антагониста pd-1 с ингибитором egfr | |
| WO2015200806A3 (en) | Humanized anti-tau antibodies | |
| HRP20191034T1 (hr) | Pripravci koji sadrže anti-cd38 protutijela i lenalidomid | |
| PE20211767A1 (es) | Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| JP2011046732A5 (enExample) | ||
| RU2016130056A (ru) | Способы лечения кожной инфекции путем введения антагониста il-4r | |
| EA200801580A1 (ru) | Новые производные пирониндола и способ их получения | |
| EA201890805A1 (ru) | Биспецифические антитела против cd3*cd19 | |
| RU2017120358A (ru) | Анти-il-1-бета антитела и способы их применения | |
| JP2017534645A5 (enExample) | ||
| JP2017506669A5 (ja) | 膠芽腫の治療に使用するための組成物及びその使用 | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| MX2019007404A (es) | Moleculas de union a adam9 y metodos de uso de las mismas. |